Reata Pharmaceuticals Announces Presentations at the 2022 International Congress for Ataxia Research


PLANO, Texas, October 20, 2022–(BUSINESS WIRE)–Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts featuring Evidence clinical data on omaveloxolone and educational data on Friedreich’s Ataxia will be presented at the 2022 International Congress for Research in Ataxia (“ICAR”) to be held in Dallas, TX, 1-4 November 2022.

Abstracts of the oral and poster presentations are listed below and will be available on the conference website at the International Congress for Ataxia Research (

Oral presentation:

Title of abstract: Direct usefulness of natural history data in clinical trial analysis: propensity-based analysis of omaveloxolone in Friedreich’s ataxia using the FA-COMS dataset

Presenter: David Lynch, MD, PhD, Director, Friedreich’s Ataxia Program, Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA
Date hour : November 4, 2022, last-minute research session at 9:00 a.m., presentation at 9:40 a.m.

Poster presentations:

Title of abstract: Efficacy of omaveloxolone in patients with Friedreich’s ataxia: delayed start analysis

Presenter: David Lynch, MD, PhD, Director, Friedreich’s Ataxia Program, Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA
Date hour : November 2 and 3, 2022, from 12 p.m. to 2 p.m.

Title of abstract: Burden of disease in patients with Friedreich’s ataxia in the United States: a retrospective analysis of real-world claims (RWE)

Presenter: Christene Song, Senior Director, Medical and Clinical Strategy, Reata
Date hour : November 2 and 3, 2022, from 12 p.m. to 2 p.m.

About Friedreich’s Ataxia

Friedreich’s ataxia is a rare, genetic, life-accelerating, debilitating, and degenerative neuromuscular disease, usually caused by a repeated expansion of trinucleotides in the first intron of the frataxin gene, which codes for the mitochondrial protein frataxin. Pathogenic repeat expansions can lead to impaired transcription and reduced expression of frataxin, which can lead to mitochondrial iron overload and poor cellular iron regulation, increased sensitivity to oxidative stress, and impaired production of mitochondrial ATP. Patients with Friedreich’s Ataxia typically present with symptoms in childhood, including progressive loss of coordination, muscle weakness, and fatigue that typically lead to motor disability in patients requiring a wheelchair in their 20s. Patients with Friedreich’s Ataxia may also present with visual impairment, hearing loss, diabetes, and cardiomyopathy. On average, patients with Friedreich’s Ataxia die in their mid-30s. Based on the literature and proprietary research, we believe that Friedreich’s Ataxia affects approximately 5,000 children and adults in the United States and 22,000 people worldwide. There are approximately 4,000 patients diagnosed with Friedreich’s Ataxia in the United States. Currently, there are no approved therapies for the treatment of Friedreich’s Ataxia.

About Omaveloxolone

Omaveloxolone is an investigational, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro- inflammatory. The FDA has granted Orphan Drug, Fast Track, and Rare Pediatric Disease Designations to omaveloxolone for the treatment of Friedreich’s Ataxia. The European Commission has granted orphan drug designation in Europe to omaveloxolone for the treatment of Friedreich’s ataxia. A New Drug Application for omaveloxolone for the treatment of Friedreich’s Ataxia is currently under review by the United States Food and Drug Administration.

About Reata

Reata is a clinical-stage biopharmaceutical company developing novel therapies for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, omaveloxolone and bardoxolone methyl (“bardoxolone”), target the important transcription factor Nrf2 which promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress and inhibiting pro-inflammatory signaling. Both omaveloxolone and bardoxolone are investigational drugs, and their safety and effectiveness have not been established by any agency.

Forward-looking statements

This press release contains certain information that contains “forward-looking statements,” including, but not limited to, statements regarding the success, cost and timing of our product development activities and clinical trials, our research, development and commercialization of our product candidates, our plans to file regulatory filings and our ability to obtain and maintain regulatory approval for our product candidates. You can identify forward-looking statements because they contain words such as ‘believes’, ‘will’, ‘may’, ‘aims’, ‘plans’, ‘models’ and ‘expects’. Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical facts nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct and results of our clinical trials and future studies preclinical and clinical trials, including the timing of initiation and the availability of data from such trials; (ii) the timing and likelihood of filings and regulatory approvals for our product candidates; (iii) if regulatory authorities determine that additional testing or data is necessary to obtain approval; (iv) the size of the potential market and the size of patient populations for our product candidates, if approved for commercial use, and market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the United States Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, under the heading ” Risk factors “. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

See the source version on


Reata Pharmaceuticals, Inc.
(972) 865-2219

Investor Relations & Media Relations:
John Hunter [email protected]
Wendy Segal [email protected]

Source link

Comments are closed.